APP antibody

Beta-amyloid peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu (2+) and Fe (3+) to Cu (+) and Fe (2+), respectively. Beta-amyloid 42 is a more effective reductant than beta-amyloid 40. Beta-amyloid peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. Beta-APP42 may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity. Also binds GPC1 in lipid rafts. The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.

Amyloid-beta precursor protein (APP) |ABPP|APPI|Alzheimer disease amyloid A4 protein homolog|Alzheimer disease amyloid protein|Amyloid precursor protein|Amyloid-beta (A4) precursor protein|Amyloid-beta A4 protein|Cerebral vascular amyloid peptide (CVAP) |PreA4|Protease nexin-II (PN-II) |N-APP|Soluble APP-alpha (S-APP-alpha) |Soluble APP-beta (S-APP-beta) |C99 Alternative names: Beta-secretase C-terminal fragment (Beta-CTF) |Amyloid-beta protein 42 (Abeta42)